This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jan Tennvall, MD, PhD; Johan Wennerberg, MD, PhD; Harald Anderson, PhD; Bo Baldetorp, PhD; Mårten Fernö, PhD; Roger Willén, MD, PhD

Arch Otolaryngol Head Neck Surg. 1993;119(8):867-870.

Abstract
• We investigated whether flow cytometric DNA index and/or ploidy status are predictors of response to chemotherapy and survival. Fifty consecutive patients with previously untreated locally advanced squamous cell carcinomas of the head and neck received induction chemotherapy consisting of three courses of cisplatin (100 mg/m²) and a subsequent 120-hour infusion of fluorouracil (1000 mg/m² per 24 hours) repeated every 3 weeks. Chemotherapy was followed by radiotherapy to a median target dose of 65 Gy and subsequent surgery for residual tumor. The median observation time was 27 months (range, 24 to 57 months). Flow cytometric DNA analysis was based on formalin-fixed and paraffin-embedded tissue from pretreatment tumor biopsy specimens. Complete response after induction chemotherapy was achieved in only 12% (2/17) of patients with diploid tumors compared with 39% (13/33) of those with nondiploid tumors. Among patients with nondiploid tumors, DNA index was higher for those responding to chemotherapy compared with the nonresponders. Complete response to chemotherapy was apparently a prerequisite for survival in the nondiploid group. Of the patients not responding to chemotherapy but responding to subsequent radiotherapy, survival was better among those with diploid tumors than among those with nondiploid tumors.

(Arch Otolaryngol Head Neck Surg. 1993;119:867-870)

Author Affiliations
From the Departments of Oncology (Drs Tennvall, Anderson, Baldetorp, and Fernö), Oto-Rhino-Laryngology (Dr Wennerberg), and Pathology (Dr Willén), University Hospital, Lund, Sweden.

Footnotes
Accepted for publication December 15, 1992.

Presented at the Third International Conference on Head and Neck Surgery, San Francisco, Calif, July 26, 1992.

Reprint requests to Department of Oncology, University Hospital, S-221 85 Lund, Sweden (Dr Tennvall).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients
Akervall et al.
Clin. Cancer Res. 2004;10:8204-8213.
ABSTRACT | FULL TEXT  

Significance of DNA Ploidy in the Treatment of T1 Glottic Carcinoma
Stern et al.
Arch Otolaryngol Head Neck Surg 1995;121:1003-1005.
ABSTRACT  

Molecular Medicine
Trees and Ensley
Arch Otolaryngol Head Neck Surg 1993;119:1173-1177.
ABSTRACT